Business Description
![ESSA Pharma Inc ESSA Pharma Inc logo](https://static.gurufocus.com/logos/0C0000AUF7.png?14)
ESSA Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA29668H7085
Description
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 383.87 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.3 | |||||
3-Year EPS without NRI Growth Rate | 16.6 | |||||
3-Year FCF Growth Rate | 16 | |||||
3-Year Book Growth Rate | 10.1 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.69 | |||||
9-Day RSI | 37.53 | |||||
14-Day RSI | 38.41 | |||||
6-1 Month Momentum % | -8.58 | |||||
12-1 Month Momentum % | 121.11 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 32.89 | |||||
Quick Ratio | 32.89 | |||||
Cash Ratio | 32.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.2 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -19.09 | |||||
ROA % | -18.65 | |||||
ROIC % | -3081.32 | |||||
ROC (Joel Greenblatt) % | -13963.24 | |||||
ROCE % | -19.07 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.59 | |||||
Price-to-Tangible-Book | 1.59 | |||||
EV-to-EBIT | -2.76 | |||||
EV-to-EBITDA | -2.77 | |||||
EV-to-FCF | -3.33 | |||||
Price-to-Net-Current-Asset-Value | 1.6 | |||||
Price-to-Net-Cash | 1.62 | |||||
Earnings Yield (Greenblatt) % | -36.23 | |||||
FCF Yield % | -10.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EPIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ESSA Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.63 | ||
Beta | 2.03 | ||
Volatility % | 73.43 | ||
14-Day RSI | 38.41 | ||
14-Day ATR ($) | 0.459252 | ||
20-Day SMA ($) | 5.1455 | ||
12-1 Month Momentum % | 121.11 | ||
52-Week Range ($) | 2.58 - 11.67 | ||
Shares Outstanding (Mil) | 44.36 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ESSA Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ESSA Pharma Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
ESSA Pharma Inc Frequently Asked Questions
What is ESSA Pharma Inc(EPIX)'s stock price today?
The current price of EPIX is $4.80. The 52 week high of EPIX is $11.67 and 52 week low is $2.58.
When is next earnings date of ESSA Pharma Inc(EPIX)?
The next earnings date of ESSA Pharma Inc(EPIX) is 2024-08-08 Est..
Does ESSA Pharma Inc(EPIX) pay dividends? If so, how much?
ESSA Pharma Inc(EPIX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |